Drugs / QPX2015
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03939429 | May → Oct 2019 | bacterial infectious disease | Qpex Biopharma, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QPX2015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03939429 ↗ |
| Known as | ceftibuten | “A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in...” PMID 38059635 ↗ Dec 2023 |
| Route | Oral | “study of oral ceftibuten” PMID 38059635 ↗ Dec 2023 |